



Embargoed for:
May 4, 2021

Media Contact:
Jenny Filbey, CEO
Mazen Animal Health, Inc.
256-417-8568
jfilbey@mazenanimalhealth.com

Mazen Animal Health, Inc. Closes Final Tranche of Series Seed Round

High-Powered Team Members and Board Members Join Mazen

Ames, IA. May 4, 2021. Mazen today announced the successful close of its Series Seed Round led by Next Level Ventures and joined by Kent Corporation, Ag Startup Engine, Ag Ventures Alliance, ISAV and Summit Ag. The company is developing orally-delivered animal vaccines that revolutionize animal disease prevention. All six first tranche investors came into the second tranche of the Series Seed to close at the targeted amount of \$2M.

"I continue to be impressed with the collaborative and supportive entrepreneurial environment in Iowa," said Jenny Filbey, CEO and Board Chair of Mazen. "With the investment, we are building a high-powered, diverse team and Board of Directors that brings experience and passion for our platform."

Rick Sibbel, DVM, joins Mazen as Strategic and Technical Lead, with deep experience in animal vaccines. Dr. Sibbel played a leading role in the development and launch of the first genetically-engineered pseudorabies vaccine, the first influenza vaccine for swine and a viral-vectored vaccine for poultry. In his 30 plus years in the Animal Health Industry total, Dr. Sibbel has helped license more than 20 vaccines for livestock and poultry.

As Mazen brings game-changing vaccines to market, Mark Zylstra joins the company as Director of Regulatory Affairs to guide the company through the regulatory process. Mr. Zylstra brings a unique background and 40 years of experience in the Animal Health Industry, including senior leadership positions in Biologics Regulatory Affairs, Manufacturing, Development and Quality Operations.

Today Mazen announced the appointment of Kevin Fields, Kent Corporation; Joel Harris, Ag Startup Engine; and Terry Coffey, Parklane Advisors to its Board of Directors. The new appointees join Directors Jenny Filbey and John Howard at the Series Seed.

"Kent Corporation views Mazen's production platform for biologics as a strong next generation technology," said Kevin Fields, President and Chief Administration Officer of Kent. "I am pleased to be part of the Board of Directors and look forward to supporting Mazen's continued successful track record."

Series Seed will fund further regulatory development for Mazen's lead Porcine Epidemic Diarrhea Virus (PEDV) vaccine candidate, scale up of pipeline products, and preparations for registration studies. The company will raise Series A funding in the second half of 2021, which will be used to complete the registration studies for licensure of the PEDV oral vaccine, build the pipeline and expand the team and capabilities.

About Mazen Animal Health, Inc.

Mazen is developing orally-delivered animal vaccines that revolutionize animal disease prevention. Mazen provides elegant solutions to the challenges associated with injectable vaccines and offers customers (1) increased production system ROI - improving the economic & labor thresholds that control the vaccination decision today; (2) a safer method of vaccine administration for both animals and workers; (3) optimized vaccine efficacy including mucosal and systemic coverage; and (4) vaccines with a global reach because of ambient temperature stability and ease of delivery. Mazen has successfully completed a lactogenic immunity study with the PEDV oral vaccine candidate and is now planning for registration studies.

www.mazenanimalhealth.com